Literature DB >> 10445856

A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer.

V Shridhar1, J Staub, B Huntley, W Cliby, R Jenkins, H I Pass, L Hartmann, D I Smith.   

Abstract

Detailed deletion mapping of chromosome 6q sequences in invasive ovarian tumors have implicated several broad regions involving 6q14-16, 6q21-23, 6q25-26, and the telomeric portion in band 6q27 as regions of frequent loss in this malignancy. In order to define regions of loss involved in the development of ovarian cancer, we used 23 polymorphic markers on 6q to examine allelic loss in 25 high-grade, late stage ovarian tumors. Four non-overlapping deletion regions were observed: (1) at 6q21-22.3 (D6S301-D6S292); (2) within a 1 cM region at 23.2-23.3 between markers D6S978-D6S1637 (at D6S311); (3) at 6q26 (between markers D6S411-D6S1277) and (4) at 6q27 with the markers D6S297 and D6S193. The highest region of loss was observed with marker D6S311 (lost in 17 of 19 informative cases, 89%) in 6q23.3, followed by D6S977 and D6S1637 (71 and 55%, respectively). The average fractional allele loss in the high-grade tumors was around 35%. Previous reports have shown 6q27 as the region of most frequent loss in invasive ovarian cancer. However, our results indicate a novel region in 6q23.3 (spanning less than 500 Kb distance between the markers) with the highest loss, implicating this region of chromosome 6q to harbor a putative tumor suppressor gene involved in the development of invasive epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10445856     DOI: 10.1038/sj.onc.1202756

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors.

Authors:  A Barghorn; E J Speel; B Farspour; P Saremaslani; S Schmid; A Perren; J Roth; P U Heitz; P Komminoth
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 2.  WWOX, large common fragile site genes, and cancer.

Authors:  Ge Gao; David I Smith
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-16

Review 3.  Very large common fragile site genes and their potential role in cancer development.

Authors:  Ge Gao; David I Smith
Journal:  Cell Mol Life Sci       Date:  2014-10-10       Impact factor: 9.261

Review 4.  Parkin in Parkinson's Disease and Cancer: a Double-Edged Sword.

Authors:  Khushnuma Wahabi; Ahmad Perwez; Moshahid A Rizvi
Journal:  Mol Neurobiol       Date:  2018-01-18       Impact factor: 5.590

5.  Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.

Authors:  Marta M Kamieniak; Daniel Rico; Roger L Milne; Ivan Muñoz-Repeto; Kristina Ibáñez; Miguel A Grillo; Samuel Domingo; Salud Borrego; Alicia Cazorla; José M García-Bueno; Susana Hernando; Jesús García-Donas; Elena Hernández-Agudo; Teresa Ramón Y Cajal; Luis Robles-Díaz; Ivan Márquez-Rodas; Maite Cusidó; Raquel Sáez; Carmen Lacambra-Calvet; Ana Osorio; Miguel Urioste; Juan C Cigudosa; Luis Paz-Ares; José Palacios; Javier Benítez; María J García
Journal:  Mol Oncol       Date:  2014-10-05       Impact factor: 6.603

6.  Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy.

Authors:  Monika Englert-Golon; Bartosz Burchardt; Bartlomiej Budny; Szymon Dębicki; Blanka Majchrzycka; Elzbieta Wrotkowska; Piotr Jasiński; Katarzyna Ziemnicka; Radosław Słopień; Marek Ruchała; Stefan Sajdak
Journal:  Oncol Lett       Date:  2017-07-17       Impact factor: 2.967

7.  PHF10 is required for cell proliferation in normal and SV40-immortalized human fibroblast cells.

Authors:  S S Banga; L Peng; T Dasgupta; V Palejwala; H L Ozer
Journal:  Cytogenet Genome Res       Date:  2010-01-06       Impact factor: 1.636

Review 8.  Post-translational modification of Parkin and its research progress in cancer.

Authors:  Dan Ding; Xiang Ao; Ying Liu; Yuan-Yong Wang; Hong-Ge Fa; Meng-Yu Wang; Yu-Qi He; Jian-Xun Wang
Journal:  Cancer Commun (Lond)       Date:  2019-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.